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Background: Zinc (Zn) and copper (Cu) may play a pivotal role in the pathogenesis of 
diabetes and diabetic complications by mediating oxidative stress. Both Zn deficiency 
and excess of Cu are associated with an increased risk of type 2 diabetes and car-
diovascular disease. We aimed to investigate the relationships between serum Zn/Cu 
ratio and glycemic status, renal function, and metabolic parameters in patients with and 
without type 2 diabetes.
Methods: We conducted a cross-sectional study on 355 subjects (149 type 2 diabetic 
and 206 non-diabetic) in whom serum Zn and Cu levels were measured at the same 
time. Associations between serum Zn/Cu ratio and clinical data were evaluated using 
multiple regression analysis. We also evaluated associations between serum Zn/Cu 
ratio and the prevalence of type 2 diabetes and glycemic control by multivariate logistic 
regression analysis.
results: Serum Zn/Cu ratio was positively associated with estimated glomerular filtration 
rate after adjustment for body mass index (BMI) (β = 0.137, p = 0.014). Plasma B-type 
natriuretic peptide levels were negatively associated with serum Zn/Cu ratio after adjust-
ment for age, sex, and BMI (β = −0.258, p = 0.032). In patients with type 2 diabetes, 
serum Zn/Cu ratio was negatively associated with plasma HbA1c levels after adjustment 
for age, sex, and BMI (β = −0.239, p = 0.003). In addition, multivariate logistic regression 
analysis revealed that the highest quartile of serum Zn/Cu ratio was associated with a 
reduced risk of poor (HbA1c ≥ 7%) glycemic control (odds ratio = 0.382; 95% confi-
dence interval, 0.165–0.884; p = 0.025) in patients with type 2 diabetes.
conclusion: Serum Zn/Cu ratio was favorably associated with renal function in all sub-
jects and glycemic control in patients with type 2 diabetes. The Zn/Cu ratio, in addition 
to the individual serum levels of trace elements, is important for metabolism in humans.
Keywords: type 2 diabetes, zinc, copper, egFr, B-type natriuretic peptide
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inTrODUcTiOn
Diabetes is a metabolic disease characterized by defects in 
insulin secretion, insulin sensitivity, or both. Trace elements, 
such as zinc (Zn) and copper (Cu), may play a pivotal role in 
the pathogenesis of diabetes and diabetic vascular complications 
by mediating oxidative stress (1–4). Several studies have shown 
that both Zn deficiency and excess of Cu are associated with 
an increased risk of type 2 diabetes and cardiovascular disease 
(CVD) (2, 3, 5–9).
Zn is a critical trace element in human health. Zn has a 
potential to be utilized for the treatment of type 2 diabetes; 
however, the epidemiologic evidence suggests that the effect 
of Zn on type 2 diabetes remains unclear (10). Up to 85% of 
the whole body Zn content is found in muscle and bones, with 
11% in the skin and liver (11). Zn is an indispensable cofactor 
for more than 300 enzymes involved in metabolism and also 
reportedly plays a role in aging, immune system, apoptosis, 
and oxidative stress (11). Although the effect of zinc supple-
mentation in the improvement of oxidative stress is contro-
versial, one of the causes that the oxidative stress is present in 
patients with type 2 diabetes is the change in zinc metabolism 
(4). Moreover, a number of studies have suggested that matrix 
metalloproteinases which include a Zn ion-binding site are 
associated with the progression of diabetic microvascular com-
plications and diabetic tendon disorders (12). Recent studies 
have demonstrated that the islet-restricted zinc transporter, 
ZnT8 (SLC30A8), regulates insulin secretion (13) and hepatic 
insulin clearance (14), suggesting that Zn is a key biological 
factor in glucose homeostasis and the risk of developing type 
2 diabetes (15).
Cu has an integral role in many enzymatic activities involved 
in modifying oxidative stress. Free Cu ions have catalytic activ-
ity in the generation of highly reactive hydroxyl radicals (16). 
Disruption of Cu homeostasis induces oxidative damage by 
free radicals; such Cu toxicity is associated with disrupted lipid 
metabolism, hepatic disorders, neurodegenerative disorders, 
and atherogenesis (17, 18). Cu ion may also play a protective 
role in the accumulation of human islet amyloid peptide, which 
is the major component of amyloid deposits in pancreatic 
β-cells of type 2 diabetic patients; however, whether or not Cu 
have a protective role in the etiology of type 2 diabetes is not 
clarified (19, 20). Excess of Cu under inflammatory conditions 
trigger oxidative stress which are present in chronic diseases 
(21). On the other hand, increased Zn ion levels may provide 
a protective effect against Cu toxicity by competing for Cu 
binding sites (16).
Epidemiological and biological studies have indicated that 
an imbalance between serum Zn and Cu levels is a causative 
factor for various diseases, particularly diabetes and CVD (2, 3, 
5–9). However, there is a lack of evidence regarding the associa-
tion between serum Zn/Cu ratio and metabolic parameters in 
humans. In this study, we aimed to investigate the relationships 
between serum Zn/Cu ratio and various parameters, such as 
hematological parameters, glycemic status, lipid profile, renal 
function, and body composition, in patients with and without 
type 2 diabetes.
MaTerials anD MeThODs
subjects
Between April 2010 and November 2014, a total of 355 individu-
als (149 type 2 diabetic patients and 206 non-diabetic patients) 
who measured both serum Zn and Cu at our hospital were inves-
tigated retrospectively. Exclusion criteria were type 1 diabetes, 
malnutrition [serum albumin (Alb)  <  3.0  g/dl], and anemia 
[plasma hemoglobin (Hb) levels  <  10  g/dl]. Chronic kidney 
disease was defined as an estimated glomerular filtration rate 
(eGFR) less than 60 mL/min/1.73 m2. Patients were diagnosed as 
having type 2 diabetes according to the Japanese diagnostic cri-
teria for type 2 diabetes (22). Briefly, diabetic type was diagnosed 
if subjects met the following criteria: fasting plasma glucose (PG) 
level of ≥126 mg/dl or casual PG level of ≥200 mg/dl or HbA1c 
level ≥6.5%. Patients with type 1 diabetes were excluded. If such 
conditions were confirmed more than once in the past or the 
presence of typical symptoms of diabetes and definite diabetic 
retinopathy were detected, patients were diagnosed as having 
type 2 diabetes. However, HbA1c level ≥6.5% alone cannot be 
defined as diabetes (22).
The patients were anonymized to protect their personal 
information. The study protocol was approved by the Medical 
Ethics Committee of the National Center for Global Health and 
Medicine Kohnodai Hospital (Reference No. NCGM-G-001912), 
and the study was performed in accordance with the Declaration 
of Helsinki.
anthropometric Measurement
Height and weight were measured using a rigid stadiometer and 
calibrated scales (seca 764, seca Co., Ltd., Birmingham, UK). Body 
mass index (BMI) was calculated as body weight in kilograms 
divided by the square of body height in meters.
Blood examination
We measured blood cell count, Alb, blood urea nitrogen, creati-
nine, eGFR, Zn, and Cu. Serum Zn and Cu levels were measured 
by atomic absorption spectrophotometry (Z6100, Hitachi Power 
Solutions Co., Ltd., Ibaraki, Japan) (23, 24). eGFR was calculated 
using the revised equation adjusted for the Japanese population 
(25). We also measured PG, hemoglobin A1c (HbA1c), B-type 
natriuretic peptide (BNP), serum total cholesterol, triglycerides 
(TG), high-density lipoprotein cholesterol (HDL-C), and insulin 
levels. Low-density lipoprotein cholesterol (LDL-C) levels were 
calculated using the Friedewald formula (26). Plasma BNP levels 
were measured using a specific immunoradiometric assay for 
human BNP (ARCHITECT BNP-JP®, ABBOTT JAPAN Co., 
Ltd., Tokyo, Japan).
Body composition analysis
Body composition was analyzed using a bioelectrical impedance 
analysis device (InBody720/S10, Biospace Co., Ltd., Tokyo, 
Japan). This method is based on the principle that lean body 
mass contains higher water and electrolyte content than fat tissue; 
hence, these tissues can be distinguished by electrical impedance. 
Segmental body composition was estimated using a patented 
TaBle 1 | Patient clinical characteristics.
Demographics
n 355
Age, years 61.1 (17.6)
Sex (male/female) 151/204
Height, cm 159.4 (9.4)
Weight, kg 61.6 (18.1)
BMI, kg/m2 24.1 (5.7)
Blood data
Red blood cell, ×104/μl 430 (55.3)
Hemoglobin, g/dl 13.1 (1.5)
Hematocrit, % 38.8 (5.2)
Biochemical data
Albumin, g/dl 4.2 (0.5)
Blood urea nitrogen, mg/dl 15.1 (7.2)
Creatinine, mg/dl 0.8 (0.3)
eGFR, ml/min/1.73 m2 75.4 (26.9)
Total cholesterol, mg/dl 187.4 (39.9)
Triglycerides, mg/dl 135.1 (91.5)
HDL cholesterol, mg/dl 54.5 (15.8)
LDL cholesterol, mg/dl 105.5 (31.5)
Plasma glucose, mg/dl 127 (60.6)
HbA1c, % 6.8 (1.8)
Serum insulin, μU/ml (n = 42) 11.6 (7.7)
Plasma BNP, pg/ml (n = 80) 53.9 (71.1)
Serum Zn, μg/dl 72.6 (15.4)
Serum Cu, μg/dl 110.8 (26.4)
Serum Zn/Cu ratio 0.69 (0.21)
Body composition (n = 119)
Skeletal muscle mass (whole body), kg 26.1 (6.7)
Right upper extremity muscle mass, kg 2.5 (0.8)
Left upper extremity muscle mass, kg 2.5 (0.8)
Right lower extremity muscle mass, kg 7.3 (1.9)
Left lower extremity muscle mass, kg 7.2 (1.9)
Body fat mass, kg 22.8 (12.5)
Body fat percentage, % 30.8 (10.7)
Values are expressed as means (SD) except for number of subjects and sex.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; BNP, B-type 
natriuretic peptide.
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8-point tactile electrode system. The device uses six frequencies 
(1, 5, 50, 250, 500, and 1000 kHz) and produces 30 impedance 
values for five body segments: the right and left upper extremities, 
trunk, and right and left lower extremities (27). A previous vali-
dation study demonstrated that both fat mass and lean body mass 
content measured using this device were highly correlated with 
measurements using dual-energy X-ray absorptiometry (28).
statistical analysis
Statistical analyses were performed using SPSS version 23 
(IBM Co., Ltd., Chicago, IL, USA). All values are expressed as 
mean ± SD. Pearson’s correlation coefficient was calculated to 
analyze the association of serum Zn/Cu ratio with physical, 
biochemical, and physiological data. Multiple regression analy-
sis was performed to test independent correlations between 
serum Zn/Cu ratio and clinical data. Differences in clinical 
data between patients with and without type 2 diabetes were 
analyzed using the paired t-test. Furthermore, multivariate 
logistic regression analyses were performed to analyze the 
association between the quartile of serum Zn/Cu ratio and 
glycemic control (good: HbA1c < 7.0%; poor: HbA1c ≥ 7.0%) 
in patients with type 2 diabetes and to determine odds ratios and 
95% confidence intervals (CI). p values < 0.05 were considered 
statistically significant.
resUlTs
characteristics of subjects
A total of 355 subjects (151 men and 204 women) were included 
in this study. The mean age was 61.1 ± 17.6 years. The number 
of patients with type 2 diabetes was 149 (42.0%). The number of 
patients with dyslipidemia, hypertension, CKD, and liver diseases 
such as fatty liver were 117 (33.0%), 94 (26.5%), 87 (24.5%), and 
35 (9.9%), respectively. Seventy two patients (20.3%) suffered 
from autoimmune diseases such as Hashimoto disease, Sjögren’s 
Syndrome, and rheumatoid arthritis. Thirty-three patients (9.3%) 
suffered from endocrine disorders such as adrenal deficiency and 
hyper/hypothyroidism. Eighteen patients (5.1%) had malignant 
diseases, such as lung cancer, prostate cancer, breast cancer, gas-
tric cancer, and colon cancer. Eleven patients (3.1%) had neuro-
degenerative diseases, such as Parkinson disease and Alzheimer 
dementia. The number of patients who had a history of CVD was 
29 (8.2%). Patient characteristics are summarized in Table 1. The 
prevalence of dyslipidemia (p < 0.001), hypertension (p < 0.001), 
and CVD (p < 0.001) was higher and the prevalence of endocrine 
disorders (p = 0.005) and autoimmune diseases (p < 0.001) was 
lower in patients with type 2 diabetes than in those without (by 
chi-square test).
associations between serum Zn/cu ratio 
and clinical Parameters in all subjects
Serum Zn/Cu ratio was inversely correlated with age and plasma 
BNP levels, whereas it was positively correlated with height, 
weight, serum Alb levels, and eGFR. Serum Zn/Cu ratio was 
also positively correlated with red blood cell count, Hb, Ht, and 
skeletal muscle mass (Table 2).
Positive associations of serum Zn/Cu ratio with serum Alb 
levels and Hb remained after adjustment for age, sex, and BMI 
(β =  0.335, p <  0.001 and β =  0.237, p =  0.002, respectively). 
Plasma BNP levels were also negatively associated with serum 
Zn/Cu ratio (β = −0.258, p =  0.032). In addition, eGFR was 
positively associated with serum Zn/Cu ratio after adjustment for 
BMI (β = 0.137, p = 0.014). However, independent associations 
between serum Zn/Cu ratio and other biochemical parameters 
were not detected.
To investigate differences in clinical parameters between 
patients with and without type 2 diabetes, patients with cancers, 
autoimmune diseases, endocrine disorders, and liver dysfunc-
tion, which were known to affect serum levels of Zn and Cu, 
were excluded from the analysis. Height, weight, BMI, red blood 
cell count, and Hb were significantly higher in patients with type 
2 diabetes than those without type 2 diabetes. Serum levels of 
HDL-C were significantly lower in patients with type 2 diabetes 
than those without type 2 diabetes (Table 3).
TaBle 3 | comparison of clinical data between patients with and without 
type 2 diabetes.
Type 2 diabetic 
patients (n = 113)
non-diabetic 
subjects (n = 110)
p-Value
Age, years 64.4 (14.7) 60.7 (20.4) 0.12
Duration of diabetes, 
years
10.5 (10) – –
Sex (male/female) 64/49 36/74 <0.001
Height, cm 161 (8.8) 157.5 (10.2) 0.009
Weight, kg 68.8 (17.9) 57.9 (17.7) <0.001
BMI, kg/m2 26.4 (5.6) 23.2 (5.6) <0.001
Red blood cell, ×104/μl 445.6 (61.2) 423.5 (50.2) 0.02
Hemoglobin, g/dl 13.7 (1.7) 13 (1.4) 0.013
Hematocrit, % 40.1 (5.8) 38.2 (4.8) 0.2
Albumin, g/dl 4.1 (0.5) 4.3 (0.5) 0.028
eGFR, ml/min/1.73 m2 71.2 (25.1) 79 (32.9) 0.054
Total cholesterol, mg/dl 184.9 (37.4) 192.7 (41.5) 0.18
Triglycerides, mg/dl 138.6 (88.7) 130.6 (85.2) 0.53
HDL cholesterol, mg/dl 51.5 (16.3) 58.1 (15.2) 0.007
LDL cholesterol, mg/dl 104.1 (30.8) 108.3 (31.5) 0.35
Plasma glucose, mg/dl 151.5 (62.2) 99.5 (21) <0.001
HbA1c, % 7.7 (1.9) 5.7 (0.4) <0.001
Serum insulin, μU/ml 10.9 (7.1) 13.1 (10) 0.56
Plasma BNP, pg/ml 55.5 (97.3) 62.5 (59.6) 0.76
Serum Zn, μg/dl 75.8 (13.7) 72.7 (18.7) 0.15
Serum Cu, μg/dl 109.9 (21) 109.4 (23) 0.42
Serum Zn/Cu ratio 0.72 (0.19) 0.69 (0.23) 0.87
Skeletal muscle mass 
(whole body), kg
26.9 (6.4) 25.3 (7.2) 0.28
Right upper extremity 
muscle mass, kg
2.7 (0.8) 2.4 (0.9) 0.13
Left upper extremity 
muscle mass, kg
2.6 (0.8) 2.4 (0.9) 0.16
Right lower extremity 
muscle mass, kg
7.6 (1.9) 7.2 (2.1) 0.36
Left lower extremity 
muscle mass, kg
7.5 (1.9) 7.1 (1.9) 0.33
Body fat mass, kg 23.9 (13.2) 23 (11.8) 0.76
Body fat percentage, % 31.2 (10.1) 31.9 (10.2) 0.75
Values are expressed as means (SD) except for sex.
BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density 
lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c; BNP, B-type 
natriuretic peptide.
TaBle 2 | correlations between serum Zn/cu ratio and clinical 
parameters in all subjects.
correlation coefficient p-Value
Demographics
Age −0.284 <0.001
Height 0.219 <0.001
Weight 0.152 0.005
BMI 0.07 0.2
Blood data
Red blood cell 0.192 0.003
Hemoglobin 0.302 <0.001
Hematocrit 0.197 0.003
Biochemical data
Albumin 0.357 <0.001
eGFR 0.144 0.008
Total cholesterol −0.046 0.44
Triglycerides 0.108 0.062
HDL cholesterol −0.063 0.3
LDL cholesterol −0.039 0.5
Plasma glucose −0.047 0.42
HbA1c −0.085 0.16
Serum insulin 0.123 0.44
Plasma BNP −0.383 <0.001
Body composition
Skeletal muscle mass (whole body) 0.189 0.039
Right upper extremity muscle mass 0.183 0.046
Left upper extremity muscle mass 0.193 0.036
Right lower extremity muscle mass 0.214 0.019
Left lower extremity muscle mass 0.224 0.014
Body fat mass −0.064 0.49
Body fat percentage −0.152 0.099
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL,  
low-density lipoprotein; HbA1c, hemoglobin A1c; BNP, B-type natriuretic peptide.
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The prevalence of dyslipidemia was higher in patients with 
type 2 diabetes than that in patients without diabetes (p < 0.001). 
However, there were no differences in the prevalence of other 
diseases, such as hypertension (p = 0.065) and CKD (p = 0.23), 
between patients with and without type 2 diabetes. In patients 
with type 2 diabetes, serum Zn/Cu ratio was positively cor-
related with height (r = 0.178, p = 0.031), serum levels of Alb 
(r = 0.46, p < 0.001), Hb (r = 0.41, p < 0.001), and Ht (r = 0.277, 
p  =  0.016) and negatively correlated with age (r  =  −0.223, 
p  =  0.006), plasma HbA1c levels (r  =  −0.193, p  =  0.019) 
(Figure  1), and plasma BNP levels (r = −0.392, p =  0.022). 
Positive associations of serum Zn/Cu ratio with serum Alb lev-
els and Hb were observed after adjustment for age, sex, and BMI 
(β = 0.494, p < 0.001 and β = 0.476, p < 0.001, respectively), 
and serum Zn/Cu ratio remained negatively associated with 
plasma HbA1c levels after the same adjustments (β = −0.239, 
p =  0.003). However, significant associations between serum 
Zn/Cu ratio and other biochemical data disappeared following 
statistical adjustments.
The multivariate logistic regression analysis revealed that the 
highest quartile of serum Zn/Cu ratio was significantly associated 
with a decreased risk of poor glycemic control (odds ratio = 0.382; 
95% CI, 0.165–0.884; p = 0.025) in patients with type 2 diabetes 
(Table 4).
DiscUssiOn
To the best of our knowledge, this is to be the first study to 
demonstrate the associations of serum Zn/Cu ratio with renal 
function, plasma BNP levels, and glycemic control in a relatively 
large population.
A positive correlation between serum Zn/Cu ratio and serum 
Alb and Hb levels is expected. Plasma Zn concentrations are 
reduced by hypoalbuminemia, as zinc is bound to Alb in the 
circulation, and Zn deficiency is a known cause of anemia (29). 
Although Cu deficiency is a potential cause of hematologic 
abnormalities (30), no significant associations between serum Cu 
levels and blood cell count were observed in this study.
An imbalance between Zn and Cu levels leads to increased 
oxidative damage in humans, contributing to the pathogenesis of 
diabetes and diabetic complications (1, 2, 31). The dysregulation 
of matrix metalloproteinases which include a Zn ion-binding site 
TaBle 4 | logistic regression analysis of glycemic control in patients 
with type 2 diabetes.
adjusted odds ratio 95% ci p-Value 
Age 1.003 0.980–1.021 0.78
Sex
Male 0.844 0.440–1.618 0.61
Female (reference)
BMI 1.045 0.982–1.111 0.16
serum Zn/cu ratio
<0.5461 (reference)
0.5462–0.6721 0.638 0.298–1.364 0.25
0.6722–0.8 0.604 0.281–1.295 0.19
>0.8 0.382 0.165–0.884 0.025
The odds ratio of good glycemic control (HbA1c < 7.0%) to poor glycemic control 
(HbA1c ≧ 7.0%) was calculated.
HbA1c, hemoglobin A1c; CI, confidence interval; BMI, body mass index.
FigUre 1 | an inverse correlation between serum Zn/cu ratio and plasma hba1c levels in patients with type 2 diabetes.
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are associated with the progression of diabetic complications via 
the interaction with advanced glycation end products in patients 
with type 2 diabetes, although the relationship between matrix 
metalloproteinases and serum Zn levels were not investigated in 
the present study (12). Furthermore, these trace elements are neces-
sary for the activity of mitochondrial antioxidant enzymes, such 
as Cu/Zn superoxide dismutase (SOD), that protect the cell from 
reactive oxygen species toxicity (32). Both Zn and Cu are essential 
for metabolism; however, an imbalance in Zn/Cu (or Cu/Zn) ratio 
may be a better indicator of metabolic disturbance than Zn or Cu 
status alone. Indeed, previous studies have demonstrated the utility 
of Cu/Zn ratio as a biomarker for vascular complications in type 2 
diabetes (33) and a predictor of mortality in elderly individuals (34).
Renal dysfunction has been shown to be induced by Cu toxic-
ity in both rats (35) and humans (36). On the other hand, Zn 
may contribute to the preservation of renal function. Kurihara 
et al. reported that Zn deficiency decreased renal blood flow and 
increased renal vascular resistance, which may be attributable to 
decreased nitric oxide activity due to the presence of increased 
concentrations of superoxide anions through low SOD activity 
in the kidneys of rats (37). Yanagisawa et al. suggested that Zn 
deficiency aggravates tubulointerstitial nephropathy in rats due 
to an increase in the action of angiotensin II and endothelin 
(38). Recently, Sun et al. demonstrated that renal function was 
improved by Zn supplementation in diabetic mice (39). Zn 
supplementation has also been shown to reduce Alb excretion 
in patients with diabetic nephropathy (40, 41). The role of Zn 
is of importance in preserving renal function. However, there is 
a lack of evidence regarding the association between Zn and/or 
Cu and renal function in humans. It is notable that the results of 
this study indicate the potential utility of serum Zn/Cu ratio as a 
biomarker for renal function.
The negative association observed between serum Zn/Cu 
ratio and plasma BNP levels in this study may be mediated by 
insulin sensitivity. An inverse association between natriuretic 
peptides and insulin resistance has been reported by previous 
studies (42–44). BNP stimulates lipolysis (45) and promotes 
muscle mitochondrial biogenesis and fat oxidation through 
upregulation of peroxisome proliferator-activated receptor-γ 
coactivator-1α (PGC-1α) (46) and increases adiponectin secre-
tion (47), thereby improving insulin resistance. In addition to 
previous reports of the association of an imbalance in Zn and Cu 
levels with increased oxidative stress and inflammation (34, 48), 
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which impair insulin secretion and action (1), Zn deficiency may 
lower SOD1 activity in pancreatic islets, which has been shown 
to increase insulin resistance (49, 50). Zn has also been shown 
to be associated with insulin secretion via metallothionein 
synthesis (51) and the zinc transporter ZnT8 (15). Recently, Zn 
has been observed to promote insulin secretion independently 
on metallothionein synthesis (52). The inverse association 
between serum Zn/Cu ratio and plasma BNP levels observed in 
this study after adjustment for age, sex, and BMI indicates that 
a higher Zn/Cu ratio may be associated with improved insulin 
sensitivity. However, we were unable to detect a significant 
association between serum Zn/Cu ratio and insulin levels. This 
inconsistency may be because of the following study limitations: 
the small sample size (n = 42) for investigating the association 
between serum Zn/Cu and insulin and confounding effects of 
oral hypoglycemic agents and diet. We are unable to confidently 
explain the negative association observed between serum Zn/Cu 
ratio and BNP in this study. Thus, further studies are required 
to elucidate the mechanisms underlying the association between 
serum Zn/Cu ratio and BNP.
Several studies have demonstrated decreased serum/plasma 
Zn levels in patients with type 2 diabetes compared with healthy 
individuals (53–55); on the contrary, serum Zn levels were not 
lower in patients with type 2 diabetes in this study. As mentioned 
above, serum Zn levels were found to be strongly affected by 
nutritional status and Hb levels; thus, no significant difference 
in serum Zn levels between patients with and without type 2 
diabetes was observed.
Low HDL-C levels in patients with type 2 diabetes may have 
been observed as serum HDL-C levels have been shown to 
decrease with impaired function in type 2 diabetes (56). Patients 
with type 2 diabetes were more obese than those without type 2 
diabetes in this study. Although no significant differences in body 
composition between patients with and without type 2 diabetes 
were found, obesity may be attributable to lower HDL-C levels in 
patients with type 2 diabetes.
The observed associations of serum Zn/Cu ratio with 
lower HbA1c levels and reduced risk of poor glycemic control 
(HbA1c ≥ 7.0%) in a population of patients with type 2 diabetes 
are noteworthy findings of this study. Although excess of intracel-
lular Zn can trigger oxidative stress from mitochondria and lead 
to neuronal degeneration (57), Zn has previously been shown 
to have beneficial effects on glycemic control as well as aging, 
immunity, and oxidative stress (58), whereas serum Cu is associ-
ated with higher HbA1c levels (31, 59). Experimental studies have 
shown that the amino acids residues involved in Cu coordination 
complexes have a key role in the formation of human islet amy-
loid peptide aggregation, which alters the autophagy pathway in 
pancreatic β-cells and leads to the development of diabetes (19, 
20). The actions of Zn and Cu in glucose metabolism appear to 
be antagonistic; hence, the balance between Zn and Cu ion con-
centrations is important. In this study, higher Zn levels were not 
associated with good glycemic control (odds ratio = 0.991; 95% CI, 
0.968–1.014; p = 0.436), whereas serum Cu levels were associated 
with glycemic control (odds ratio = 1.024; 95% CI, 1.007–1.041, 
p = 0.006). However, the high serum Zn/Cu ratio was associated 
with good glycemic control in patients with type 2 diabetes. This 
result suggests that not only Zn and Cu status alone but also 
Zn/Cu ratio should be considered when evaluating the relation-
ship between these trace elements in patients with diabetes.
This study had several limitations. First, a causal relationship 
between serum Zn/Cu ratio and renal function and/or glycemic 
control could not be evaluated because of the retrospective and 
observational nature of this study. Second, we were unable to 
evaluate the utility of other biomarkers in assessing Zn and Cu 
status, such as urinary and other tissue concentrations of Zn 
and Cu. Zn and Cu concentrations are known to be affected by 
other factors, such as inflammation, and fasting or postprandial 
states (60, 61). However, blood Zn and Cu levels are currently 
considered to be useful and reliable biomarkers (60, 61). Third, 
we are unable to generalize the results of this study to healthy 
individuals or other populations. The subjects included in this 
study had a high prevalence of comorbid diseases, such as hyper-
tension, dyslipidemia, fatty liver, autoimmune disease, CKD, and 
CVD, besides type 2 diabetes. Neurodegenerative disorders could 
also undergo changes in serum Zn and Cu levels. Although we 
excluded subjects with malnutrition and anemia, comorbidities 
and medications may have affected the observed associations of 
Zn and Cu status with other parameters. We should also perform 
a further investigation in healthy controls. Fourth, other con-
founding factors, such as dietary intake, smoking and drinking 
habits, and physical activity, should also be considered. Fifth, we 
were unable to provide a value for the most desirable balance 
between Zn and Cu from the results of this study. Despite these 
limitations, we were able to demonstrate significant associations 
of serum Zn/Cu ratio with renal function, glycemic control, and 
a number of metabolic parameters, providing new insights in the 
management of type 2 diabetes.
cOnclUsiOn
The findings of this study demonstrate that serum Zn/Cu ratio 
is significantly associated with renal function in all subjects and 
glycemic control in patients with type 2 diabetes. Serum Zn/Cu 
ratio was negatively associated with plasma BNP levels. Imbalance 
between Zn and Cu levels induces oxidative stress and insulin 
resistance, which may lead to progression of diabetes and diabetic 
complications. Zn/Cu ratio, in addition to individual levels of each 
trace element status alone, appears to have an important effect 
on metabolism, indicating that these trace elements may play a 
key role in the pathogenesis of metabolic diseases. We, clinicians 
should note that serum Zn/Cu ratio could be a better indicator 
for human metabolism as compared with Zn or Cu status alone.
aUThOr cOnTriBUTiOns
HH performed the study, conducted the data analyses, and 
drafted and revised the manuscript. YK contributed to the data 
collection and analyses. HY critically reviewed the manuscript 
and the scientific interpretations of study results. All the authors 
read and approved the final manuscript.
acKnOWleDgMenTs
The authors appreciate the supporting of Tomoko Kaga who 
cooperated to collect the data.
7Hamasaki et al. Serum Zn/Cu Ratio and Type 2 Diabetes
Frontiers in Endocrinology | www.frontiersin.org November 2016 | Volume 7 | Article 147
reFerences
1. Ceriello A. Oxidative stress and glycemic regulation. Metabolism (2000) 
49(2 Suppl 1):27–9. doi:10.1016/S0026-0495(00)80082-7 
2. Soinio M, Marniemi J, Laakso M, Pyörälä K, Lehto S, Rönnemaa T. Serum 
zinc level and coronary heart disease events in patients with type 2 diabetes. 
Diabetes Care (2007) 30(3):523–8. doi:10.2337/dc06-1682 
3. Tanaka A, Kaneto H, Miyatsuka T, Yamamoto K, Yoshiuchi K, Yamasaki Y, 
et al. Role of copper ion in the pathogenesis of type 2 diabetes. Endocr J (2009) 
56(5):699–706. doi:10.1507/endocrj.K09E-051 
4. Cruz KJ, de Oliveira AR, Marreiro Ddo N. Antioxidant role of zinc in diabetes 
mellitus. World J Diabetes (2015) 6(2):333–7. doi:10.4239/wjd.v6.i2.333 
5. Białkowska M, Hoser A, Szostak WB, Dybczyński R, Sterliński S, Nowicka G, 
et al. Hair zinc and copper concentration in survivors of myocardial infarction. 
Ann Nutr Metab (1987) 31(5):327–32. doi:10.1159/000177287 
6. Kok FJ, Van Duijn CM, Hofman A, Van der Voet GB, De Wolff FA, Paays CH, 
et al. Serum copper and zinc and the risk of death from cancer and cardiovas-
cular disease. Am J Epidemiol (1988) 128(2):352–9. 
7. Ford ES. Serum copper concentration and coronary heart disease among US 
adults. Am J Epidemiol (2000) 151(12):1182–8. doi:10.1093/oxfordjournals.
aje.a010168 
8. Little PJ, Bhattacharya R, Moreyra AE, Korichneva IL. Zinc and cardiovascu-
lar disease. Nutrition (2010) 26(11–12):1050–7. doi:10.1016/j.nut.2010.03.007 
9. Yary T, Virtanen JK, Ruusunen A, Tuomainen TP, Voutilainen S. Serum 
zinc and risk of type 2 diabetes incidence in men: the Kuopio Ischaemic 
Heart Disease Risk Factor Study. J Trace Elem Med Biol (2016) 33:120–4. 
doi:10.1016/j.jtemb.2015.11.001 
10. Ruz M, Carrasco F, Sánchez A, Perez A, Rojas P. Does zinc really “metal” 
with diabetes? The epidemiologic evidence. Curr Diab Rep (2016) 16(11):111. 
doi:10.1007/s11892-016-0803-x 
11. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME. Zinc and 
human health: an update. Arch Toxicol (2012) 86(4):521–34. doi:10.1007/
s00204-011-0775-1 
12. Abreu BJ, de Brito Vieira WH. Metalloproteinase changes in diabetes. Adv Exp 
Med Biol (2016) 920:185–90. doi:10.1007/978-3-319-33943-6_17 
13. Rutter GA. Think zinc: new roles for zinc in the control of insulin secretion. 
Islets (2010) 2(1):49–50. doi:10.4161/isl.2.1.10259 
14. Tamaki M, Fujitani Y, Hara A, Uchida T, Tamura Y, Takeno K, et  al. The 
diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance. 
J Clin Invest (2013) 123(10):4513–24. doi:10.1172/JCI68807 
15. Wijesekara N, Chimienti F, Wheeler MB. Zinc, a regulator of islet function 
and glucose homeostasis. Diabetes Obes Metab (2009) 11(Suppl 4):202–14. 
doi:10.1111/j.1463-1326.2009.01110.x 
16. Gaetke LM, Chow CK. Copper toxicity, oxidative stress, and antioxidant 
nutrients. Toxicology (2003) 189(1–2):147–63. doi:10.1016/S0300-483X(03) 
00159-8 
17. Gaetke LM, Chow-Johnson HS, Chow CK. Copper: toxicological relevance 
and mechanisms. Arch Toxicol (2014) 88(11):1929–38. doi:10.1007/
s00204-014-1355-y 
18. Heinecke JW, Rosen H, Chait A. Iron and copper promote modification of low 
density lipoprotein by human arterial smooth muscle cells in culture. J Clin 
Invest (1984) 74(5):1890–4. doi:10.1172/JCI111609 
19. Magrì A, La Mendola D, Nicoletti VG, Pappalardo G, Rizzarelli E. New 
insight in copper-ion binding to human islet amyloid: the contribution of 
metal-complex speciation to reveal the polypeptide toxicity. Chemistry (2016) 
22(37):13287–300. doi:10.1002/chem.201602816 
20. Sánchez-López C, Cortés-Mejía R, Miotto MC, Binolfi A, Fernández CO, 
Del Campo JM, et al. Copper coordination features of human islet amyloid 
polypeptide: the type 2 diabetes peptide. Inorg Chem (2016). doi:10.1021/acs.
inorgchem.6b01963 
21. Pereira TC, Campos MM, Bogo MR. Copper toxicology, oxidative stress and 
inflammation using zebrafish as experimental model. J Appl Toxicol (2016) 
36(7):876–85. doi:10.1002/jat.3303 
22. Committee of the Japan Diabetes Society on the Diagnostic Criteria of 
Diabetes Mellitus; Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, et al.  
Report of the committee on the classification and diagnostic criteria of 
diabetes mellitus. J Diabetes Investig (2010) 1(5):212–28. doi:10.1111/ 
j.2040-1124.2010.00074.x 
23. Meret S, Henkin RI. Simultaneous direct estimation by atomic absorption 
spectrophotometry of copper and zinc in serum, urine, and cerebrospinal 
fluid. Clin Chem (1971) 17(5):369–73. 
24. Abe A, Yamashita S, Noma A. Sensitive, direct colorimetric assay for copper 
in serum. Clin Chem (1989) 35(4):552–4. 
25. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equa-
tions for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 
(2009) 53(6):982–92. doi:10.1053/j.ajkd.2008.12.034 
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of 
low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin Chem (1972) 18(6):499–502. 
27. Anderson LJ, Erceg DN, Schroeder ET. Utility of multifrequency bioelectrical 
impedance compared with dual-energy x-ray absorptiometry for assessment 
of total and regional body composition varies between men and women. Nutr 
Res (2012) 32(7):479–85. doi:10.1016/j.nutres.2012.05.009 
28. Faria SL, Faria OP, Cardeal MD, Ito MK. Validation study of multi-frequency 
bioelectrical impedance with dual-energy X-ray absorptiometry among 
obese patients. Obes Surg (2014) 24(9):1476–80. doi:10.1007/s11695-014- 
1190-5 
29. Wieringa FT, Dijkhuizen MA, Fiorentino M, Laillou A, Berger J. Determination 
of zinc status in humans: which indicator should we use? Nutrients (2015) 
7(5):3252–63. doi:10.3390/nu7053252 
30. Halfdanarson TR, Kumar N, Li CY, Phyliky RL, Hogan WJ. Hematological 
manifestations of copper deficiency: a retrospective review. Eur J Haematol 
(2008) 80(6):523–31. doi:10.1111/j.1600-0609.2008.01050.x 
31. Viktorínová A, Toserová E, Krizko M, Duracková Z. Altered metabolism 
of copper, zinc, and magnesium is associated with increased levels of 
glycated hemoglobin in patients with diabetes mellitus. Metabolism (2009) 
58(10):1477–82. doi:10.1016/j.metabol.2009.04.035 
32. Reddi AR, Culotta VC. SOD1 integrates signals from oxygen and glu-
cose to repress respiration. Cell (2013) 152(1–2):224–35. doi:10.1016/ 
j.cell.2012.11.046 
33. Karahan SC, Değer O, Orem A, Uçar F, Erem C, Alver A, et al. The effects of 
impaired trace element status on polymorphonuclear leukocyte activation in 
the development of vascular complications in type 2 diabetes mellitus. Clin 
Chem Lab Med (2001) 39(2):109–15. doi:10.1515/CCLM.2001.019 
34. Malavolta M, Giacconi R, Piacenza F, Santarelli L, Cipriano C, Costarelli L, 
et  al. Plasma copper/zinc ratio: an inflammatory/nutritional biomarker as 
predictor of all-cause mortality in elderly population. Biogerontology (2010) 
11(3):309–19. doi:10.1007/s10522-009-9251-1 
35. Galhardi CM, Diniz YS, Faine LA, Rodrigues HG, Burneiko RC, Ribas BO, 
et al. Toxicity of copper intake: lipid profile, oxidative stress and susceptibility 
to renal dysfunction. Food Chem Toxicol (2004) 42(12):2053–60. doi:10.1016/ 
j.fct.2004.07.020 
36. Iyanda AA, Anetor J, Adeniyi FA. Altered copper level and renal dysfunction 
in Nigerian women using skin-whitening agents. Biol Trace Elem Res (2011) 
143(3):1264–70. doi:10.1007/s12011-011-8962-8 
37. Kurihara N, Yanagisawa H, Sato M, Tien CK, Wada O. Increased 
renal vascular resistance in zinc-deficient rats: role of nitric oxide 
and superoxide. Clin Exp Pharmacol Physiol (2002) 29(12):1096–104. 
doi:10.1046/j.1440-1681.2002.03783.x 
38. Yanagisawa H, Nodera M, Wada O. Zinc deficiency aggravates tubulointersti-
tial nephropathy caused by ureteral obstruction. Biol Trace Elem Res (1998) 
65(1):1–6. doi:10.1007/BF02784109 
39. Sun W, Wang Y, Miao X, Wang Y, Zhang L, Xin Y, et al. Renal improvement by 
zinc in diabetic mice is associated with glucose metabolism signaling medi-
ated by metallothionein and Akt, but not Akt2. Free Radic Biol Med (2014) 
68:22–34. doi:10.1016/j.freeradbiomed.2013.11.015 
40. Parham M, Amini M, Aminorroaya A, Heidarian E. Effect of zinc supplemen-
tation on microalbuminuria in patients with type 2 diabetes: a double blind, 
randomized, placebo-controlled, cross-over trial. Rev Diabet Stud (2008) 
5(2):102–9. doi:10.1900/RDS.2008.5.102 
41. Khan MI, Siddique KU, Ashfaq F, Ali W, Reddy HD, Mishra A. Effect of high-
dose zinc supplementation with oral hypoglycemic agents on glycemic control 
and inflammation in type-2 diabetic nephropathy patients. J Nat Sci Biol Med 
(2013) 4(2):336–40. doi:10.4103/0976-9668.117002 
42. Olsen MH, Hansen TW, Christensen MK, Gustafsson F, Rasmussen S, 
Wachtell K, et  al. N-terminal pro brain natriuretic peptide is inversely 
8Hamasaki et al. Serum Zn/Cu Ratio and Type 2 Diabetes
Frontiers in Endocrinology | www.frontiersin.org November 2016 | Volume 7 | Article 147
related to metabolic cardiovascular risk factors and the metabolic syn-
drome. Hypertension (2005) 46(4):660–6. doi:10.1161/01.HYP.0000179575. 
13739.72 
43. Neeland IJ, Winders BR, Ayers CR, Das SR, Chang AY, Berry JD, et al. Higher 
natriuretic peptide levels associate with a favorable adipose tissue distribution 
profile. J Am Coll Cardiol (2013) 62(8):752–60. doi:10.1016/j.jacc.2013. 
03.038 
44. Hamasaki H, Yanai H, Kakei M, Noda M, Ezaki O. The association between 
daily physical activity and plasma B-type natriuretic peptide in patients with 
glucose intolerance: a cross-sectional study. BMJ Open (2015) 5(1):e006276. 
doi:10.1136/bmjopen-2014-006276 
45. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic 
peptides: a new lipolytic pathway in human adipocytes. FASEB J (2000) 
14(10):1345–51. doi:10.1096/fj.14.10.1345 
46. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, et  al. 
Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades pro-
mote muscle mitochondrial biogenesis and prevent obesity. Diabetes (2009) 
58(12):2880–92. doi:10.2337/db09-0393 
47. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al. Natriuretic 
peptides enhance the production of adiponectin in human adipocytes and in 
patients with chronic heart failure. J Am Coll Cardiol (2009) 53(22):2070–7. 
doi:10.1016/j.jacc.2009.02.038 
48. Guo CH, Chen PC, Yeh MS, Hsiung DY, Wang CL. Cu/Zn ratios are associated 
with nutritional status, oxidative stress, inflammation, and immune abnor-
malities in patients on peritoneal dialysis. Clin Biochem (2011) 44(4):275–80. 
doi:10.1016/j.clinbiochem.2010.12.017 
49. Wang X, Vatamaniuk MZ, Roneker CA, Pepper MP, Hu LG, Simmons RA, 
et al. Knockouts of SOD1 and GPX1 exert different impacts on murine islet 
function and pancreatic integrity. Antioxid Redox Signal (2011) 14(3):391–401. 
doi:10.1089/ars.2010.3302 
50. Lei XG, Vatamaniuk MZ. Two tales of antioxidant enzymes on β cells 
and diabetes. Antioxid Redox Signal (2011) 14(3):489–503. doi:10.1089/ 
ars.2010.3416 
51. Islam MS, Loots du T. Diabetes, metallothionein, and zinc interactions: a 
review. Biofactors (2007) 29(4):203–12. doi:10.1002/biof.5520290404 
52. Hardy AB, Prentice KJ, Froese S, Liu Y, Andrews GK, Wheeler MB. Zip4 
mediated zinc influx stimulates insulin secretion in pancreatic beta cells. PLoS 
One (2015) 10(3):e0119136. doi:10.1371/journal.pone.0119136 
53. Kinlaw WB, Levine AS, Morley JE, Silvis SE, McClain CJ. Abnormal zinc 
metabolism in type II diabetes mellitus. Am J Med (1983) 75(2):273–7. 
doi:10.1016/0002-9343(83)91205-6 
54. Walter RM Jr, Uriu-Hare JY, Olin KL, Oster MH, Anawalt BD, Critchfield JW, 
et  al. Copper, zinc, manganese, and magnesium status and complications 
of diabetes mellitus. Diabetes Care (1991) 14(11):1050–6. doi:10.2337/
diacare.14.11.1050 
55. Aguilar MV, Saavedra P, Arrieta FJ, Mateos CJ, González MJ, Meseguer  I, 
et  al. Plasma mineral content in type-2 diabetic patients and their associa-
tion with the metabolic syndrome. Ann Nutr Metab (2007) 51(5):402–6. 
doi:10.1159/000108108 
56. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract 
Endocrinol Metab (2009) 5(3):150–9. doi:10.1038/ncpendmet1066 
57. Granzotto A, Sensi SL. Intracellular zinc is a critical intermediate in the excito-
toxic cascade. Neurobiol Dis (2015) 81:25–37. doi:10.1016/j.nbd.2015.04.010 
58. Jansen J, Karges W, Rink L. Zinc and diabetes – clinical links and molec-
ular mechanisms. J Nutr Biochem (2009) 20(6):399–417. doi:10.1016/ 
j.jnutbio.2009.01.009 
59. Naka T, Kaneto H, Katakami N, Matsuoka TA, Harada A, Yamasaki Y, et al. 
Association of serum copper levels and glycemic control in patients with type 
2 diabetes. Endocr J (2013) 60(3):393–6. doi:10.1507/endocrj.EJ12-0342 
60. Lowe NM, Fekete K, Decsi T. Methods of assessment of zinc status in humans: 
a systematic review. Am J Clin Nutr (2009) 89(6):2040S–51S. doi:10.3945/
ajcn.2009.27230G 
61. Harvey LJ, Ashton K, Hooper L, Casgrain A, Fairweather-Tait SJ. Methods of 
assessment of copper status in humans: a systematic review. Am J Clin Nutr 
(2009) 89(6):2009S–24S. doi:10.3945/ajcn.2009.27230E 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Hamasaki, Kawashima and Yanai. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
